Jove
Visualize
Contact Us

Related Experiment Videos

New monoclonal antibodies

M R Costanzo1

  • 1Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.

Current Opinion in Cardiology
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies like OKT3 are crucial for preventing organ transplant rejection. Research is advancing towards fully human antibody fragments and tolerance-inducing strategies using antibodies with donor antigens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of nesiritide in patients with acute decompensated heart failure.

The New England journal of medicine·2011
Same author

Flow panel reactive antibody monitoring following heart transplantation.

Transplantation proceedings·2001
Same author

Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death.

Circulation·2001
Same author

Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: prognostic variables and outcomes.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2001
Same author

Hypotension, acidosis, and vasodilatation syndrome post-heart transplantation: lack of association with genetic cytokine profile.

Transplantation proceedings·2001
Same author

Assessing coronary blood flow dynamics with the TIMI frame count method: comparison with simultaneous intracoronary Doppler and ultrasound.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2001
Same journal

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same journal

Viability testing for guiding revascularization in ischemic cardiomyopathy.

Current opinion in cardiology·2026
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Biotechnology

Background:

  • Monoclonal antibody technology is vital in medicine, particularly for organ transplant rejection.
  • OKT3, a murine monoclonal antibody targeting the CD3 receptor on T cells, is widely used clinically.
  • OKT3 effectively reverses rejection in heart transplant recipients resistant to standard immunosuppression.

Purpose of the Study:

  • To review the role of monoclonal antibodies in preventing and treating organ transplant rejection.
  • To discuss the clinical application and advancements in monoclonal antibody technology for transplantation.

Main Methods:

  • Review of existing clinical data and research on monoclonal antibodies in transplantation.
  • Focus on OKT3's efficacy and the development of humanized and fully human antibody fragments.

Related Experiment Videos

  • Exploration of strategies for inducing allograft tolerance.

    • Main Results:

    • OKT3 demonstrates success in reversing refractory rejection in heart transplant patients.
    • Partially human monoclonal antibodies reduce recipient sensitization.
    • Development of fully human antibody fragments (Fab') is under investigation.

    Conclusions:

    • Monoclonal antibodies are essential tools in managing organ transplant rejection.
    • Ongoing research focuses on humanized antibodies, antibody fragments, and combination therapies for enhanced tolerance.